Mechanistically, low NAD+ levels due to CD38 activation limited NAD+ bioavailability for SIRT1 deacetylase activity, thereby enhancing acetylated EZH2 and repressing downstream RUNX3 expression, which resulted in decreased levels of cytotoxic-related molecules and increased risk for infections [126]. The gene discussed is CD38; the disease is infection.